Approval of Augtyro (repotrectinib) for patients with ROS1-positive NSCLC by China’s NMPA – Zai Lab
Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for Augtyro (repotrectinib) for the treatment of adult… read more.